HALO · Healthcare
Halozyme Therapeutics Inc
24/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
32
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$11.6B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About HALOZYME THERAPEUTICS INC
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption…
Who's behind the signal
Every informed buyer we can see on HALO, across all three feeds.
Hedge funds · 6
Citadel Advisors
New position
Gotham Asset Mgmt (Greenblatt)
Increased +70%
D.E. Shaw & Co
Increased +13%
Bridgewater Associates (Dalio)
Decreased −9%
AQR Capital Management
Decreased −12%
Millennium Management (Englander)
Decreased −68%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 5 on record
Disclosures from 2017-11-06 to 2022-08-05
The newest disclosure we hold for this stock is 2022-08-05.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2022-08-05 | Josh Gottheimer · D-NJ | House | Sold | $1,001 - $15,000 |
| 2021-08-20 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
| 2020-10-22 | Gilbert Ray Cisneros, Jr. · D-CA | House | Bought | $1,001 - $15,000 |
| 2020-10-19 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
| 2017-11-06 | Mark R. Warner · D-VA | Senate | Sold | $500,001 - $1,000,000 |
Not a model pick — but on our radar.
HALOZYME THERAPEUTICS INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
1
New positions
2
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of Citadel Advisors's portfolio
Trust weight: 1.1×
% of portfolio
0.1%
Position change
+70%
0.1% of Gotham Asset Mgmt's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+13%
0.1% of D.E. Shaw & Co's portfolio
Trust weight: 1.3×
% of portfolio
0.1%
Position change
−9%
0.1% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−12%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−68%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to HALOZYME THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell HALOZYME THERAPEUTICS INC or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime